Expert Commentaries

Clinical trials targeting Lp(a) – What’s new?

August 28, 2025

Since I last discussed cinical trial data on novel Lp(a)-targeting medicines in development – antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs) and small molecules –some exciting new data have been reported and important new studies are underway.

Read article >

What are our research highlights since Lp(a) Forum launch?

April 3, 2025

Dr Elias Björnson, University of Gothenburg, Sweden In the 12 months since Lp(a) Forum was launched in April 2024, we have seen some remarkable progress in the field of Lp(a) research. As scientists, we now understand a lot more about the atherogenicity of Lp(a) particles, and the specific lipid components, such as diacylglycerols (DG) and […]

Why test for Lp(a)?

October 16, 2024

Professor Keith Ferdinand, Tulane University School of Medicine, New Orleans, USA, discusses the advantages of Lp(a) testing for patients and their families.

Read article >

Lp(a) and coronary plaque progression: Insights from imaging

July 3, 2024

Contrast CT is a very powerful technique for looking inside coronary arteries. It enables us to visualise and, with the help of modern AI systems, to quantify the amount of different types of plaque in an artery. This provides very powerful information because, if you want to predict the likelihood of a myocardial infarction (MI), at a simple level, the more plaques you have, the more likely you will have a plaque rupture event and then an MI.

Read article >

The Genetics of Lp(a)

July 2, 2024

Genetic studies have paved the way for our understanding of Lp(a) regulation and, most importantly, of the causal association between Lp(a) and cardiovascular (CV) outcomes, and the potential for current and future therapeutic developments.

Read article >

Diversity in Lp(a) across ancestry and gender

May 23, 2024

Plasma Lp(a) concentration varies widely between individuals and according to ethnic background. An estimated 1-1.5 billion people worldwide have elevated Lp(a) (≥50 mg/dL/≥ 100-125 nmol/L), with highest levels in those of African and South Asian ancestry, followed by White and Latino populations, and lowest levels in East Asian populations.

Read article >

Clinical trials targeting Lp(a) – What’s new?

What are our research highlights since Lp(a) Forum launch?

Why test for Lp(a)?

Lp(a) and coronary plaque progression: Insights from imaging

The Genetics of Lp(a)

Diversity in Lp(a) across ancestry and gender

Educational Partners and Supporters